Chlamydia & Gonorrhea in Men
Urethritis, Epididymitis, Orchitis, Infertility Risk, and Antibiotic-Resistant Gonorrhea
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Treatments FDA-approved; CDC STI Treatment Guidelines 2021 define standard regimens
Reference only. Not medical advice.
What can go wrong
Untreated, ascending infection causes epididymitis and epididymo-orchitis, which can produce scrotal pain, swelling, and in some cases obstructive damage that contributes to male-factor infertility. Reactive arthritis (formerly Reiter syndrome) can follow chlamydial urethritis. The dominant population-level risk is antimicrobial-resistant gonorrhea: ceftriaxone-resistant and multidrug-resistant strains have been documented internationally (including high-level resistant clones reported from Japan, the UK, and Australia), and the CDC and WHO both classify drug-resistant N. gonorrhoeae as an urgent threat. Disseminated gonococcal infection (arthritis-dermatitis syndrome) is an uncommon but serious complication.
This is something to take to a clinician. The Atlas can tell you what is known about chlamydia & gonorrhea in men in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Chlamydia trachomatis and Neisseria gonorrhoeae are the two most frequently reported bacterial STIs. In men they classically cause urethritis (discharge, dysuria) and can ascend to cause epididymitis and, less commonly, orchitis. A large share of male chlamydial and gonococcal infections are asymptomatic, which sustains transmission. The CDC's 2021 STI Treatment Guidelines updated first-line therapy: doxycycline 100 mg twice daily for 7 days for chlamydia (replacing single-dose azithromycin as preferred), and a single 500 mg intramuscular ceftriaxone dose for gonorrhea (a doubling of the prior 250 mg dose), with azithromycin co-treatment dropped from the routine regimen. Antimicrobial-resistant gonorrhea is the central threat: N. gonorrhoeae has sequentially defeated sulfonamides, penicillins, tetracyclines, and fluoroquinolones, and ceftriaxone is the last reliably effective monotherapy.
The two most common reportable bacterial STIs in men, and gonorrhea is running out of antibiotics.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Chlamydia trachomatis is an obligate intracellular bacterium that infects columnar epithelium of the urethra; doxycycline and azithromycin interrupt its protein synthesis. Neisseria gonorrhoeae is a Gram-negative diplococcus that adheres to and invades mucosal epithelium via pili and Opa proteins, provoking a neutrophilic response that produces the purulent discharge. Ceftriaxone, a third-generation cephalosporin, inhibits penicillin-binding proteins in the gonococcal cell wall. In men, ascending infection along the vas deferens to the epididymis produces epididymitis; sexually transmitted epididymitis in younger men is most often chlamydial or gonococcal, whereas in older men or those practicing insertive anal sex enteric organisms (E. coli) matter more.
Why male asymptomatic carriage drives the epidemic
Screening guidelines have historically focused on women because of the fertility stakes of pelvic inflammatory disease, leaving asymptomatic men as an under-screened reservoir. A man with silent urethral chlamydia can transmit for months. The CDC does not recommend universal chlamydia screening of all heterosexual men, but does recommend at least annual screening of sexually active men who have sex with men (MSM) at all exposed anatomic sites (urethral, rectal, pharyngeal), because extragenital infections are common and are usually missed by urine-only testing.
What people get wrong
Often saidIf there are no symptoms there is no infection
ActuallyRoughly half of male chlamydial infections and a meaningful share of gonococcal infections are asymptomatic, yet remain transmissible and can still ascend to cause epididymitis.
Often saidA single antibiotic dose always cures gonorrhea
ActuallyRising resistance means yesterday's regimens fail today. The CDC has repeatedly escalated gonorrhea therapy, and surveillance for ceftriaxone treatment failure is an active global concern.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Chlamydia first-line (2021)
- Doxycycline 100 mg BID x 7 days
- Gonorrhea first-line (2021)
- Ceftriaxone 500 mg IM single dose
- Asymptomatic male chlamydia
- Roughly half of infections
- Ascending complication
- Epididymitis (esp. men under 35)
- Reportable
- Yes, in the US (nationally notifiable)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Chlamydia & Gonorrhea in Men. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
CDC STI Treatment Guidelines2021
Changed chlamydia first-line to doxycycline 100 mg BID x 7 days and gonorrhea to ceftriaxone 500 mg IM monotherapy
Geisler et al., NEJM (chlamydia treatment efficacy)2015
Azithromycin vs doxycycline non-inferiority questioned for rectal/symptomatic infection, supporting the later doxycycline-preferred shift
WHO Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP)ongoing
Documents rising minimum inhibitory concentrations to ceftriaxone and azithromycin worldwide